Revvity Inc. $RVTY Shares Sold by Corient Private Wealth LP

Key Points

• Corient Private Wealth reduced its Revvity stake by 11.8% in the second quarter, selling 21,548 shares and retaining 160,410 shares valued at approximately $17.8 million. Institutional investors collectively own 86.65% of the company.
• Revvity’s shares recently rose 3.4% to $128.57, near the upper end of their 52-week range. The company exceeded quarterly earnings and revenue expectations, reporting $1.41 in EPS and $729.69 million in revenue, though revenue declined 1.3% year over year.
• The company declared a quarterly dividend of $0.07 per share, representing a 0.2% annualized yield. Analysts maintain a consensus “Hold” rating with an average price target of $116.57.

Corient Private Wealth LP decreased its position in shares of Revvity Inc. (NYSE:RVTY - Free Report) by 11.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 160,410 shares of the company's stock after selling 21,548 shares during the period. Corient Private Wealth LP owned about 0.14% of Revvity worth $17,847,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Ascentis Independent Advisors acquired a new stake in shares of Revvity during the first quarter valued at about $29,000. Global Retirement Partners LLC purchased a new stake in shares of Revvity during the second quarter worth about $51,000. SJS Investment Consulting Inc. lifted its stake in shares of Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company's stock worth $47,000 after acquiring an additional 521 shares in the last quarter. Summit Securities Group LLC lifted its stake in shares of Revvity by 294.6% in the first quarter. Summit Securities Group LLC now owns 663 shares of the company's stock worth $58,000 after acquiring an additional 495 shares in the last quarter. Finally, Contravisory Investment Management Inc. purchased a new position in Revvity in the first quarter valued at about $66,000. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Stock Up 3.4%

Shares of Revvity stock opened at $128.57 on Tuesday. The business has a 50-day moving average price of $118.03 and a 200 day moving average price of $103.47. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $133.00. The firm has a market cap of $14.35 billion, a P/E ratio of 61.22, a P/E/G ratio of 2.26 and a beta of 1.09. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. During the same quarter last year, the business posted $1.18 EPS. Revvity's quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts forecast that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity's dividend payout ratio (DPR) is presently 13.33%.

Analyst Ratings Changes

RVTY has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on Revvity in a research note on Tuesday, June 2nd. They set a "peer perform" rating for the company. Sanford C. Bernstein initiated coverage on Revvity in a research report on Friday, June 26th. They issued a "market perform" rating and a $115.00 target price on the stock. TD Cowen reiterated a "buy" rating on shares of Revvity in a research note on Wednesday, July 15th. Wall Street Zen downgraded shares of Revvity from a "buy" rating to a "hold" rating in a research report on Sunday, August 16th. Finally, UBS Group assumed coverage on shares of Revvity in a research note on Wednesday, September 9th. They issued a "neutral" rating and a $140.00 price target for the company. Four research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $116.57.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer's Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.